Olema Pharmaceuticals shares drop 4.46% in after-hours trading after latest earnings report lacks performance data.

Olema Pharmaceuticals, Inc. plunged 4.46% in after-hours trading, as the company's latest financial report lacked specific performance data, raising investor concerns about future growth. The company's main product, palazestrant, is undergoing multiple clinical trials, and its progress will impact market competitiveness. Olema's stock has declined 11.43% over the past five days, reflecting a bearish market sentiment.